Zip-Code Level Disadvantage as a Predictor of Metastatic Breast Cancer at Diagnosis and Delayed Treatment Initiation

邮政编码级别的劣势作为诊断时转移性乳腺癌和延迟治疗启动的预测因素

阅读:1

Abstract

BACKGROUND: Metastatic breast cancer remains a significant public health issue, associated with worse outcomes and limited treatment options. While tumor biology influences disease progression, social and geographic disparities also contribute to late-stage diagnosis. The Distressed Communities Index (DCI), a zip-code level measure of economic hardship, captures structural disadvantage more comprehensively than traditional socioeconomic indicators. This study evaluates whether higher DCI scores are associated with metastatic stage and treatment delays, independent of clinical and demographic factors. PATIENTS AND METHODS: We conducted a retrospective cohort study of women aged ≥ 18 years diagnosed or treated for in situ (DCIS) and invasive breast cancer (2018-2022) at a comprehensive cancer center. Zip codes were linked to DCI scores. Multinomial logistic regression, adjusted for age, race, ethnicity, insurance status, tumor subtype, and clinical palpable mass, assessed the association between DCI and cancer stage. Analysis of covariance compared time with treatment across DCI groups. RESULTS: Among 2024 women (38% Black, 39% Hispanic), 76.8% resided in high DCI areas. High DCI was associated with twice the likelihood of metastatic disease at diagnosis compared with localized stage (ref: low DCI, aOR 2.16, 95% CI 2.00-2.34, p < 0.001) after adjustment. High DCI patients also experienced longer time to treatment initiation, including adjuvant chemotherapy (119 versus 137 days, p = 0.024), radiation (103 versus 133 days, p < 0.001), and surgery (71.2 versus 87.4 days, p < 0.001), after adjustment for stage. CONCLUSIONS: Leveraging DCI may help identify high-risk zip codes and guide targeted screening to reduce disparities in outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。